PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.66%
Negative revenue growth while QCOM stands at 3.81%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.81%
Negative gross profit growth while QCOM is at 0.56%. Joel Greenblatt would examine cost competitiveness or demand decline.
-18.38%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-18.60%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-18.76%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-17.86%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-17.86%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.91%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.81%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
6.82%
Maintaining or increasing dividends while QCOM cut them. John Neff might see a strong edge in shareholder returns.
4.17%
OCF growth under 50% of QCOM's 20.85%. Michael Burry might suspect questionable revenue recognition or rising costs.
6.33%
FCF growth under 50% of QCOM's 28.76%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
160.86%
10Y revenue/share CAGR under 50% of QCOM's 563.22%. Michael Burry would suspect a lasting competitive disadvantage.
43.38%
5Y revenue/share CAGR under 50% of QCOM's 88.67%. Michael Burry would suspect a significant competitive gap or product weakness.
-7.30%
Negative 3Y CAGR while QCOM stands at 107.92%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
168.15%
10Y OCF/share CAGR under 50% of QCOM's 342.56%. Michael Burry would worry about a persistent underperformance in cash creation.
26.50%
Below 50% of QCOM's 145.83%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
5.20%
3Y OCF/share CAGR under 50% of QCOM's 117.49%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
137.70%
Below 50% of QCOM's 379.05%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
463.32%
5Y net income/share CAGR above 1.5x QCOM's 65.93%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-41.46%
Negative 3Y CAGR while QCOM is 64.34%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
117.37%
Below 50% of QCOM's 341.69%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
36.69%
Below 50% of QCOM's 95.20%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
11.74%
Below 50% of QCOM's 63.86%. Michael Burry suspects a serious short-term disadvantage in building book value.
2060.94%
10Y dividend/share CAGR above 1.5x QCOM's 887.23%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
172.72%
5Y dividend/share CAGR 1.25-1.5x QCOM's 116.01%. Bruce Berkowitz verifies that high dividend hikes remain sustainable, not a sign of over-distribution.
129.94%
3Y dividend/share CAGR above 1.5x QCOM's 83.82%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-21.06%
Firm’s AR is declining while QCOM shows 7.39%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.29%
We show growth while QCOM is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.59%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-1.31%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.06%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-5.98%
Our R&D shrinks while QCOM invests at 3.93%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.86%
We cut SG&A while QCOM invests at 7.18%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.